4-aminopyridine


Also found in: Medical, Wikipedia.

4-aminopyridine

[¦fȯr ə‚mē·nō′pī·rə‚dēn]
(organic chemistry)
C5H6N2 White crystals with a melting point of 158.9°C; soluble in water; used as a repellent for birds. Abbreviated 4-AP.
Mentioned in ?
References in periodicals archive ?
channel inhibitors (glibenclamide + TEA + iberiotoxin + 4-aminopyridine + barium chloride).
Acorda) announced that the European Patent Office (EPO) Opposition Division has upheld amended claims covering a sustained release formulation of fampridine (trade name: FAMPYRA), also known as dalfampridine or 4-aminopyridine, for improving walking speed in patients with multiple sclerosis (MS) with twice daily dosing at 10 mg.
These studies provided the rationale for the development of the potassium channel blocker, 4-aminopyridine, as the first Food and Drug Administration (FDA)-approved therapy for restoring function in MS [7].
Strychnine and 4-aminopyridine used as avicides are not only highly toxic to target birds but also pose secondary hazards to predatory and scavenger animals.
An animal experiment showed that neuromuscular block from a combination of neuromuscular blocking drugs and local anaesthetic is only partially reversed by neostigmine (18), but is effectively antagonised by 4-aminopyridine, a selective blocker of [K.
Results showed that astaxanthin exhibited a dose-dependent inhibition of 4-aminopyridine (4-AP)-evoked release of glutamate.
The 4-aminopyridine (4-AP) model of epilepsy allows for the induction of epileptiform activity while preserving excitatory and inhibitory synaptic activity.
Fampridine-SR is another such treatment--a sustained-release formula of 4-aminopyridine, which blocks potassium channels.
For 4-aminopyridine (4-AP) documentation of fatigue improvement is still scarce.
4-Aminopyridine acts as a weak base and a calcium mobilizing agent in triggering meiosis reinitiation and activation in the Japanese clam Ruditapes philippinarum.
Significantly, in vivo application of compounds of the instant invention established, on the basis of SSEP testing, that the compounds provide longer lasting effects at lower concentrations than comparable treatment with the known agent 4-aminopyridine.
NRI), a biopharmaceutical company focused on treatments for peripheral neuropathies, has announced that its request for orphan drug designation of 4-Aminopyridine has been granted for treatment of chronic functional motor and sensory deficits resulting from Guillain-Barre Syndrome (GBS).